Soligenix Q2 FY26 net loss narrows to $2 million; revenue flat at no revenue
SNGX•Quarterly results
Soligenix posted a net loss of $2 million, or ($0.12) per share, for the quarter ended June 30, 2026.
Research and development expense fell 41.18% to $1 million, due to lower costs tied to the terminated Phase 3 FLASH2 trial.
General and administrative expense was flat at $1.1 million; revenue was no revenue.
Cash position and development focus
Cash totaled about $9.8 million as of June 30, 2026, providing runway into the second quarter of 2028.
HyBryte development was discontinued after the Phase 3 FLASH2 study; focus remains on SGX945 for Behçet's disease and ThermoVax, including CEPI funding efforts.
